首页> 美国卫生研究院文献>Cancer Science >Immune infiltration in renal cell carcinoma
【2h】

Immune infiltration in renal cell carcinoma

机译:肾细胞癌的免疫浸润

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immune infiltration of tumors is closely associated with clinical outcome in renal cell carcinoma (RCC). Tumor‐infiltrating immune cells (TIICs) regulate cancer progression and are appealing therapeutic targets. The purpose of this study was to determine the composition of TIICs in RCC and further reveal the independent prognostic values of TIICs. CIBERSORT, an established algorithm, was applied to estimate the proportions of 22 immune cell types based on gene expression profiles of 891 tumors. Cox regression was used to evaluate the association of TIICs and immune checkpoint modulators with overall survival (OS). We found that CD8+ T cells were associated with prolonged OS (hazard ratio [HR] = 0.09, 95% confidence interval [CI].01‐.53; P = 0.03) in chromophobe carcinoma (KICH). A higher proportion of regulatory T cells was associated with a worse outcome (HR = 1.59, 95% CI 1.23‐.06; P < 0.01) in renal clear cell carcinoma (KIRC). In renal papillary cell carcinoma ( style="fixed-case">KIRP), M1 macrophages were associated with a favorable outcome ( style="fixed-case">HR = .43, 95% style="fixed-case">CI .25‐.72; P < 0.01), while M2 macrophages indicated a worse outcome ( style="fixed-case">HR = 2.55, 95% style="fixed-case">CI 1.45‐4.47; P < 0.01). Moreover, the immunomodulator molecules style="fixed-case">CTLA4 and style="fixed-case">LAG3 were associated with a poor prognosis in style="fixed-case">KIRC, and style="fixed-case">IDO1 and style="fixed-case">PD‐L2 were associated with a poor prognosis in style="fixed-case">KIRP. This study indicates style="fixed-case">TIICs are important determinants of prognosis in style="fixed-case">RCC meanwhile reveals potential targets and biomarkers for immunotherapy development.
机译:肿瘤的免疫浸润与肾细胞癌(RCC)的临床结局密切相关。肿瘤浸润免疫细胞(TIIC)调节癌症进展,并且是有吸引力的治疗靶标。这项研究的目的是确定RCC中TIIC的组成,并进一步揭示TIIC的独立预后价值。已建立的算法CIBERSORT被用于基于891个肿瘤的基因表达谱估计22种免疫细胞类型的比例。 Cox回归用于评估TIIC和免疫检查点调节剂与总生存期(OS)的关联。我们发现发色癌(KICH)中CD8 + T细胞与OS延长相关(危险比[HR] = 0.09,95%置信区间[CI] .01-.53; P = 0.03)。肾透明细胞癌(KIRC)中比例更高的调节性T细胞与较差的预后相关(HR = 1.59,95%CI 1.23-.06; P <0.01)。在肾乳头状细胞癌( style =“ fixed-case”> KIRP )中,M1巨噬细胞与良好的预后相关( style =“ fixed-case”> HR =。43 ,95% style =“ fixed-case”> CI .25‐.72; P <0.01),而M2巨噬细胞则预示不良结果( style =“ fixed-case”> HR span> = 2.55,95% style =“ fixed-case”> CI 1.45-4.47; P <0.01)。此外,免疫调节剂分子 style =“ fixed-case”> CTLA 4和 style =“ fixed-case”> LAG 3与 style =“ fixed-case“> KIRC 和 style =” fixed-case“> IDO 1和 style =” fixed-case“> PD -L2与一个 style =“ fixed-case”> KIRP 的预后不良。这项研究表明 style =“ fixed-case”> TIIC s是 style =“ fixed-case”> RCC 预后的重要决定因素,同时揭示了免疫疗法发展的潜在靶标和生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号